Lenti-CEA CAR (scFv-ζ, MFE23)-VP(VP-CAR-LC804)

The ready-to-use lentiviral particles of Lenti-CEA CAR (scFv-ζ, MFE23)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (MFE23)-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.


Specifications


Type of Therapeutics
Chimeric Antigen Receptor
Target
CEA
Expression Cassette
scFv (MFE23)-CD3ζ
Clone
MFE23
Promotor
CMV
Packaging System
Lentivirus
Packaging Cell
293T
Targeting Diseases
Advanced CEA+ malignancy

Target


Introduction
Members of the CEACAM subfamily, including CEACAM5, belong to the CEA gene family. For general information on the CEA gene family, see CEACAM1 (MIM 109770).[supplied by OMIM, Oct 2009]
Alternative Names
CEACAM5; carcinoembryonic antigen-related cell adhesion molecule 5; CEA; CD66e; renal cell carcinoma; RCC; renal cell carcinoma; scFv; FcεRIγ; Chimeric antigen receptor; T cell; Retrovirus; CARs; Lentivirus; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; BW431/26
Gene ID

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products


OthersCarcinoma

Online Inquiry

Name:
* Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.
CB Promise
CONTACT US
45-1 Ramsey Road, Shirley, NY 11967, USA
USA: 1-631-871-5806
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-871-5806
Fax: 1-631-207-8356
Email:

Europe
Ringstrasse 4, 64401 Gross-Bieberau, Germany
Tel: 44-207-097-1828

Distributors

To view the contact information for a specific location, select the desired country:

Australia
australia

FOLLOW US ON